米ギリアド、コロナ薬候補「レムデシビル」で肯…(写真=ロイター)
日本経済新聞
5Picks
コメント
注目のコメント
Adaptive COVID-19 Treatment Trial (ACTT)
https://clinicaltrials.gov/ct2/show/NCT04280705
プレスリリース
1. Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19
2. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
-- Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir --